Subtype
Anorectal Neoplasm
CI-CAN-00001814Explore in graph →
Non-malignant504 active trials1 approved drugs6 evidence items
- NCIt
- C215222
Loading cancer entity…
Subtype
CI-CAN-00001814Explore in graph →
Clinical trials
2,046 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07314528 | Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer | not yet recruiting | Phase 2 | 42 | St. James's Hospital, IrelandOTHER | 0 | Jan 2, 2026 | clinicaltrials |
| NCT04141449 | A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation(Potlako+) | active not recruiting | Phase 2 | 874 | Brigham and Women's HospitalOTHER | 1 | Dec 31, 2025 |
| clinicaltrials |
| NCT06715839 | Target-specific immunoPET Imaging of Digestive System Carcinoma | recruiting | N/A | 400 | RenJi HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07154173 | Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer | recruiting | — | 300 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors(VARTUTRACE) | recruiting | Early Phase 1 | 32 | Var2 PharmaceuticalsINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06640283 | Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes(ANA) | recruiting | Phase 2 | 150 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07296237 | Beyond Survival: Addressing Gynecological and Sexual Health in Women After Radiotherapy for Anal Cancer(DACG VI) | recruiting | — | 80 | Aarhus University HospitalOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07297030 | SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer | not yet recruiting | Phase 2 | 37 | Sun Yat-sen UniversityOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT05902533 | REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation(REDEL) | active not recruiting | Phase 2 / Phase 3 | 33 | University of CincinnatiOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05943444 | Comparison of Postoperative Anal Function Between Parks and Bacon Techniques in Low Rectal Cancer | recruiting | N/A | 256 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07038122 | Reducing the Resection Range After Neoadjuvant Therapy for Locally Advanced Upper Rectal and Rectosigmoid Junction Cancers(RESET) | active not recruiting | N/A | 874 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07284992 | SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC | recruiting | Phase 2 | 208 | Shandong Provincial HospitalOTHER_GOV | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06380101 | Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)(NEAAR-LARC) | recruiting | N/A | 30 | University of South FloridaOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT07221058 | Adaptive Radiation Boost for Rectal Cancer(ARBOR) | recruiting | Phase 1 | 37 | Fox Chase Cancer CenterOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT07269249 | Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer(RW-NEDOS) | recruiting | — | 50 | National Cancer Institute, NaplesOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07269912 | Application of Multimodal MRI in Histological Grading and Prognostic Assessment of Rectal Cancer | not yet recruiting | — | 400 | Sichuan Cancer Hospital and Research InstituteOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT06236633 | Safety & Efficacy of Ischemic Preconditioning by Embolization of the Inferior Mesenteric Artery in Surgery for Tumors of Lower and Middle Rectum(AMIREMBOL_2) | recruiting | N/A | 30 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06522256 | Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial(HPVsign) | recruiting | N/A | 100 | ANRS, Emerging Infectious DiseasesOTHER_GOV | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07160647 | The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)(Neo-IT) | active not recruiting | Phase 2 | 29 | Sir Run Run Shaw HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07258797 | Short Course or Long Course Radiotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer(SHOOL) | not yet recruiting | N/A | 150 | Rajiv Gandhi Cancer Institute & Research Center, IndiaOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07248020 | A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue(BCMRECRAD) | not yet recruiting | Phase 2 | 72 | Chang Gung Memorial HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07243938 | Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) | not yet recruiting | Phase 2 | 70 | Tao ZhangOTHER | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07127497 | Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma | active not recruiting | Phase 2 | 50 | The First Affiliated Hospital of Anhui Medical UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07241143 | Extra-Peritoneal Tunneling Versus Conventional Drain Fixation After Anterior or Low Anterior Resection(ExPeTuD) | not yet recruiting | N/A | 596 | Yeungnam University HospitalOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07236827 | A Comparison of Endoscopic Synchronous Injection and Submucosal Dissection(ESISD) and Conventional Endoscopic Submucosal Dissection(CESD) for Granular Mixed Nodular Laterally Spreading Tumor in the Rectum (LST-G-M)(ESISD vs CESD) | not yet recruiting | N/A | 60 | Taihe HospitalOTHER | 0 | Nov 19, 2025 | clinicaltrials |
| NCT01941641 | Colon Neoadjuvant FOLFOXIRI Study | active not recruiting | Phase 2 | 40 | Chinese University of Hong KongOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03997435 | FOLFOXIRI With or Without Intensification for Rectal Cancer | active not recruiting | Phase 2 | 72 | CCTUOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06640049 | A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China(China AZUR-1) | active not recruiting | Phase 2 | 23 | GlaxoSmithKlineINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT00996710 | Genomic Structural Variation in Cancer Susceptibility | active not recruiting | — | 1,275 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | recruiting | — | 50,000 | Massive Bio, Inc.INDUSTRY | 2 | Oct 28, 2025 | clinicaltrials |
| NCT05040815 | Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer(INSPIRE) | recruiting | Phase 2 | 45 | AHS Cancer Control AlbertaOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07179692 | CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors | recruiting | Phase 1 | 108 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07198165 | SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC | recruiting | Phase 2 | 104 | Ruijin HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT02505750 | Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma(OPERA) | active not recruiting | Phase 3 | 148 | Centre Antoine LacassagneOTHER | 3 | Sep 29, 2025 | clinicaltrials |
| NCT07192627 | ESD in Locally Advanced Rectal Cancer Following CRT | not yet recruiting | — | 20 | Assiut UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT07189520 | 1. SAFE-AI ONCO-TRACK: Multimodal GenAI for Early Detection of Minimal Residual Disease and Recurrence in Gastrointestinal Oncology(ONCO-TRACK) | not yet recruiting | — | 700 | Università Politecnica delle MarcheOTHER | 0 | Sep 24, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT03975491 | The Exercise And Colorectal Cancer Treatment Trial(EXACT) | active not recruiting | N/A | 60 | Pennington Biomedical Research CenterOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07175636 | QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer | not yet recruiting | Phase 2 | 66 | Sun Yat-sen UniversityOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT03958240 | Deciphering Mechanisms Underlying Cancer Immunogenicity(DECIDE) | recruiting | N/A | 1,100 | Institut Claudius RegaudOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07161115 | Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer(REFIRT) | not yet recruiting | Phase 2 | 60 | Longhao LiOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05938322 | Ketogenic Diet Compliance in Patients Undergoing Radiotherapy for Pelvic Cancers(KOMPARC) | recruiting | N/A | 194 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT04949646 | Intraoperative Neuromonitoring of Pelvic Autonomous Nerve Plexus During Total Mesorectal Excision | recruiting | N/A | 44 | Larissa University HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06770270 | Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)(PUCRT) | recruiting | Phase 2 | 68 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06207981 | Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA(KANALRAD) | recruiting | Phase 3 | 310 | Federation Francophone de Cancerologie DigestiveOTHER | 2 | Sep 2, 2025 | clinicaltrials |
| NCT07150949 | Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) | recruiting | Phase 2 | 138 | Fudan UniversityOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05576480 | SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer(SPARC) | recruiting | Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Aug 28, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 2, 2026source: clinicaltrials